The role of minocycline in ischemia-reperfusion injury: a comprehensive review of an old drug with new implications.

Abstract

Minocycline is a semi-synthetic tetracycline that inhibits bacterial protein synthesis and hence is used for the treatment of many infectious diseases. Over the years, many other interesting properties of minocycline have been identified and been used to make patents which include anti-inflammatory, anti-apoptotic, matrix metalloproteinase inhibitor and free oxygen radical scavenger activity. Ischemia-reperfusion injury is a concern for almost every clinical specialty and minocycline seems to be an attractive cytoprotective agent that can ameliorate the damage due to these properties. Ischemia-reperfusion injury is a complex process and involves various pathways that lead to cell death. This review focuses on the body of evidence describing various proposed mechanisms of action of minocycline and its current experimental use in various animal models of ischemia-reperfusion injury.

• Authors: Berkin O Ulgen, Matthew G Field, Waqas Qureshi, Richard A Knight, Anastasis Stephanou, David S Latchman, Diego Vasquez, Sean P Barry, Louis Saravolatz 2nd, Gabriele M Scarabelli, Giuseppe Faggian, Alessandro Mazzucco, Louis Saravolatz, Carol Chen-Scarabelli, Tiziano M Scarabelli
• Journal: Recent patents on cardiovascular drug discovery (Recent Pat Cardiovasc Drug Discov) Vol. 6 Issue 2 Pg. 123-32 (May 2011) United Arab Emirates
• PMID: 21599619 (Publication Type: Journal Article, Review)

Chemical References

• Anti-Bacterial Agents
• Minocycline

Topics

• Animals
• Anti-Bacterial Agents (pharmacology)
• Apoptosis (drug effects)
• Cytoprotection (drug effects)
• Disease Models, Animal
• Humans
• Minocycline (pharmacology)
• Patents as Topic
• Reperfusion Injury (drug therapy, physiopathology)